Reports

Ideas That Generate Results

List of Figures:

Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014

List of Tables:

Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
Table 9-2: Mylan - Strengths and Weaknesses
Table 9-3: 3M - Key Financials (Million US$), 2012-2014
Table 9-4: 3M - Strengths and Weaknesses
Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
Table 9-6: Novartis - Strengths and Weaknesses
Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
Table 9-8: Astrazeneca - Strengths and Weaknesses
Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
Table 9-13: Sanofi - Strengths and Weaknesses
Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
Table 9-17: Merck & Co- Strengths and Weaknesses